Liquidia Corporation (LQDA): one to watch?

Watch, not buy yet — real profits and a beat-not-miss quarter, but the drop reflects genuine risk from single-drug dependence and ongoing patent litigation.

👀 WATCH Fundamentals81/100

Fell 22% in 9 trading day(s) — now $71.05

Why LQDA dropped

The stock fell after Q2 2026 earnings that actually beat estimates on both revenue and EPS, but investors reacted to the modest size of the beat, profit-taking after a huge prior run-up, and growing concern about Liquidia's near-total dependence on one drug (YUTREPIA) plus unresolved patent litigation with rival United Therapeutics (UTHR).

Fwd P/E 12.6Op margin 49.8%Rev growth 1842.7%Debt/equity 93.7%Analyst upside 51.7%

How this scored 81/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 30.7%

✅ Generates cash Free cash flow $74M

✅ Not drowning in debt Debt/equity 93.7% (limit 200%)

✅ Can pay its bills Current ratio 2.3 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 25/25

Operating margin 49.8% 9/9

Net profit margin 30.7% 8/8

Return on equity 131.8% 8/8

Growth Is it getting bigger, or dying? 19/25

Revenue growth 1842.7% 9/9

Earnings growth unknown 2/8

Expected profit change 328.0% 8/8

Value Is it cheap right now? 17/25

Forward P/E 12.6 9/10

PEG ratio unknown 2/8

Analyst target upside 51.7% 6/7

Balance sheet Will it survive? 20/25

Debt / equity 93.7% 6/10

Current ratio 2.3 7/8

Free cash flow $74M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for LQDA — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-08-21. Research only — not financial advice.